{
    "topic": "opioid_crisis",
    "source": "Associated Press",
    "bias": 1,
    "url": "https://apnews.com/fb54abbce60e1fe44926becb84e86edf",
    "title": "North America trade pact deals rare setback to Big Pharma",
    "date": "2019-12-19",
    "authors": "Paul Wiseman, Linda A. Johnson, Kevin Freking",
    "content": "FILE - This June 15 , 2018 , file photo shows pharmaceuticals in North Andover , Mass . A revamped North American trade deal is nearing passage in Congress , giving both the White House and House Democrats cause to claim victory . There is relief , too , for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States , Canada and Mexico . But the pact left at least one surprising loser : The pharmaceutical industry , a near-invincible lobbying powerhouse in Washington . ( AP Photo/Elise Amendola , File )\nFILE - This June 15 , 2018 , file photo shows pharmaceuticals in North Andover , Mass . A revamped North American trade deal is nearing passage in Congress , giving both the White House and House Democrats cause to claim victory . There is relief , too , for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States , Canada and Mexico . But the pact left at least one surprising loser : The pharmaceutical industry , a near-invincible lobbying powerhouse in Washington . ( AP Photo/Elise Amendola , File )\nA revamped North American trade deal nearing passage in Congress gives both the White House and Democrats a chance to claim victory and offers farmers and businesses clearer rules governing the vast flow of goods among the United States , Canada and Mexico .\nBut the pact leaves at least one surprising loser : the pharmaceutical industry , a near-invincible lobbying powerhouse in Washington .\nTo satisfy House Democrats , the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs . Democrats opposed what they called a giveaway to the industry that could have locked in inflated prices by stifling competition . Top examples of the injected drugs made from living cells include medications to fight cancer and immune disorders such as rheumatoid arthritis .\n\u201c This is one of the first times we \u2019 ve actually seen pharma lose , \u201d said Rep. Earl Blumenauer , an Oregon Democrat who leads a subcommittee on trade . \u201c They have a remarkable track record because they are a huge political force . They spend lots of money on lobbying , on advertising , on campaign contributions . But we held firm , and we won on all counts . \u201d\nThe removal of the provision also helped illustrate just how potent a political issue sky-high drug prices have become . It was a reminder , too , that President Donald Trump repeatedly pledged to work to lower drug prices .\nLast week , drug manufacturers absorbed another \u2014 though likely only temporary \u2014 defeat when House Democrats passed legislation , along party lines , that would authorize Medicare to use its influence in the marketplace to negotiate lower prices from drug companies . The bill is thought to have no chance of passage , though , in the Republican-led Senate .\nYet the revamped U.S.-Mexico-Canada Agreement , Trump \u2019 s rewrite of the 25-year-old North American Free Trade Act , seems set to clear Congress without the biologics protection that the drug industry had sought . , the House The full House voted 385-41 on Thursday to approve it . The Senate isn \u2019 t likely to take it up until January .\n\u201c It \u2019 s not a mystery , \u2019 \u2019 said Rep. Jan Schakowsky , an Illinois Democrat who helped negotiate with the administration . \u201c If you poll the American people , the cost of pharmaceuticals is a really big deal . It \u2019 s at the top of the list . \u2019 \u2019\nThe trade agreement the administration reached last year with Mexico and Canada gave biologics 10 years of protection from cheaper near-copies known as biosimilars . Among the leading biologics are the anti-cancer drug Rituxan and Humira and Enbrel , which fight immune disorders .\nThe industry \u2014 and the Trump administration \u2014 had argued that manufacturers of biologics require years of protection to profit from their drugs before biosimilars should be allowed to cut into sales . Otherwise , they contend , brand-name drug companies and biotech startups that rely on money from venture capital firms would have little incentive to invest in developing new medicines .\n\u201c The announcement made today puts politics over patients , \u201d the leading drug industry trade group , PhRMA , said in a statement last week . \u201c Eliminating the biologics provision in the USMCA removes vital protections for innovators while doing nothing to help U.S. patients afford their medicines or access future treatments and cures . \u2019 \u2019\nThe industry also rejected the notion that the biologics provision would keep drug prices high and hurt consumers . Existing U.S. law , they noted , already gives makers of biologics 12 years \u2019 protection , more than the proposed 10 years in the USMCA . But the provision the Democrats succeeded in removing would have forced Mexico to expand biologics \u2019 monopoly from five years and Canada from eight , potentially hurting U.S. consumers who seek lower drug prices in those countries .\nWhat \u2019 s more , Democrats argued , if Congress had expanded the biologics \u2019 monopoly in the USMCA , it would have prevented lawmakers from ever scaling back that monopoly to , say , the seven years that the Obama administration had once proposed .\nFor Big Pharma , the setback marked a sharp turnabout . Four years ago , the drug industry helped scuttle an Obama administration trade deal with 11 Pacific Rim countries , arguing that a provision establishing eight years of protection for biologics was not sufficient . Now the latest U.S. trade deal contains no biologics protections at all .\nBack in 2006 , the industry scored a major victory when it helped push legislation through Congress that added prescription drug coverage for Medicare recipients but barred the government from negotiating lower prices . That restriction opened a \u201c Pandora \u2019 s box \u201d that paved the way for unsustainable price hikes , said Steve Brozak , an analyst at WBB Securities .\nDrug makers began raising prices of existing drugs several times a year , sometimes totaling more than 20 % annually . They also started launching biologics with list prices topping six figures a year . In May , U.S. regulators approved a one-time gene therapy , Zolgensma , with an eye-popping price of $ 2.1 million per patient .\nA backlash has been growing , especially after news reports and congressional hearings exposed stories of patients rationing medicine and even dying because they couldn \u2019 t afford insulin or other drugs .\nDrugmakers have \u201c been on defense more than we \u2019 ve ever seen , \u201d said David Certner , legal counsel for AARP .\nLast year , Certner noted , Congress dealt the industry two losses : First , by increasing the discounts that drug makers must give to seniors with high drug costs who have landed in a Medicare coverage gap . Then , months later , lawmakers rejected industry efforts to reverse that change .\nAnd in January , the industry lost perhaps its biggest champion in Congress when Sen. Orrin Hatch , R-Utah , retired .\nTrump has long promised to address drug prices . On Wednesday , the administration moved ahead with a plan to allow Americans to safely and legally gain access to lower-priced medicines from abroad . So far , most of Trump \u2019 s drug-price initiatives have gone nowhere . His trade team negotiated biologics protections into the USMCA .\nFacing public anger , Democratic resistance and the fact that Canada and Mexico had no reason to support the protections for biologics , the administration yielded . When it reached a deal with House Democrats on the USMCA last week , the biologics provision was out .\n\u201c Clearly , getting rid of the biologic provision was a step backwards , \u201d U.S. Trade Representative Robert Lighthizer said Tuesday in an interview with the Fox Business Network . \u201c And that was a compromise . You know , there are consequences of the Democrats \u2019 control of the House . And that was necessary . And I \u2019 m sorry about that . \u201d\nJeffrey Francer , general counsel for the Association for Accessible Medicines , which represents generic and biosimilar drug companies , put it another way : \u201c The president decided not to fall on his sword for Big Pharma . \u2019 \u2019",
    "content_original": "FILE - This June 15, 2018, file photo shows pharmaceuticals in North Andover, Mass. A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington. (AP Photo/Elise Amendola, File)\n\nFILE - This June 15, 2018, file photo shows pharmaceuticals in North Andover, Mass. A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington. (AP Photo/Elise Amendola, File)\n\nA revamped North American trade deal nearing passage in Congress gives both the White House and Democrats a chance to claim victory and offers farmers and businesses clearer rules governing the vast flow of goods among the United States, Canada and Mexico.\n\nBut the pact leaves at least one surprising loser: the pharmaceutical industry, a near-invincible lobbying powerhouse in Washington.\n\nTo satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs. Democrats opposed what they called a giveaway to the industry that could have locked in inflated prices by stifling competition. Top examples of the injected drugs made from living cells include medications to fight cancer and immune disorders such as rheumatoid arthritis.\n\n\u201cThis is one of the first times we\u2019ve actually seen pharma lose,\u201d said Rep. Earl Blumenauer, an Oregon Democrat who leads a subcommittee on trade. \u201cThey have a remarkable track record because they are a huge political force. They spend lots of money on lobbying, on advertising, on campaign contributions. But we held firm, and we won on all counts.\u201d\n\nThe removal of the provision also helped illustrate just how potent a political issue sky-high drug prices have become. It was a reminder, too, that President Donald Trump repeatedly pledged to work to lower drug prices.\n\nLast week, drug manufacturers absorbed another \u2014 though likely only temporary \u2014 defeat when House Democrats passed legislation, along party lines, that would authorize Medicare to use its influence in the marketplace to negotiate lower prices from drug companies. The bill is thought to have no chance of passage, though, in the Republican-led Senate.\n\nYet the revamped U.S.-Mexico-Canada Agreement, Trump\u2019s rewrite of the 25-year-old North American Free Trade Act, seems set to clear Congress without the biologics protection that the drug industry had sought. , the House The full House voted 385-41 on Thursday to approve it. The Senate isn\u2019t likely to take it up until January.\n\n\u201cIt\u2019s not a mystery,\u2019\u2019 said Rep. Jan Schakowsky, an Illinois Democrat who helped negotiate with the administration. \u201cIf you poll the American people, the cost of pharmaceuticals is a really big deal. It\u2019s at the top of the list.\u2019\u2019\n\nThe trade agreement the administration reached last year with Mexico and Canada gave biologics 10 years of protection from cheaper near-copies known as biosimilars. Among the leading biologics are the anti-cancer drug Rituxan and Humira and Enbrel, which fight immune disorders.\n\nThe industry \u2014 and the Trump administration \u2014 had argued that manufacturers of biologics require years of protection to profit from their drugs before biosimilars should be allowed to cut into sales. Otherwise, they contend, brand-name drug companies and biotech startups that rely on money from venture capital firms would have little incentive to invest in developing new medicines.\n\n\u201cThe announcement made today puts politics over patients,\u201d the leading drug industry trade group, PhRMA, said in a statement last week. \u201cEliminating the biologics provision in the USMCA removes vital protections for innovators while doing nothing to help U.S. patients afford their medicines or access future treatments and cures.\u2019\u2019\n\nThe industry also rejected the notion that the biologics provision would keep drug prices high and hurt consumers. Existing U.S. law, they noted, already gives makers of biologics 12 years\u2019 protection, more than the proposed 10 years in the USMCA. But the provision the Democrats succeeded in removing would have forced Mexico to expand biologics\u2019 monopoly from five years and Canada from eight, potentially hurting U.S. consumers who seek lower drug prices in those countries.\n\nWhat\u2019s more, Democrats argued, if Congress had expanded the biologics\u2019 monopoly in the USMCA, it would have prevented lawmakers from ever scaling back that monopoly to, say, the seven years that the Obama administration had once proposed.\n\n\u201cWe would have been locked in,\u2019\u2019 Schakowsky said.\n\nFor Big Pharma, the setback marked a sharp turnabout. Four years ago, the drug industry helped scuttle an Obama administration trade deal with 11 Pacific Rim countries, arguing that a provision establishing eight years of protection for biologics was not sufficient. Now the latest U.S. trade deal contains no biologics protections at all.\n\nBack in 2006, the industry scored a major victory when it helped push legislation through Congress that added prescription drug coverage for Medicare recipients but barred the government from negotiating lower prices. That restriction opened a \u201cPandora\u2019s box\u201d that paved the way for unsustainable price hikes, said Steve Brozak, an analyst at WBB Securities.\n\nDrug makers began raising prices of existing drugs several times a year, sometimes totaling more than 20% annually. They also started launching biologics with list prices topping six figures a year. In May, U.S. regulators approved a one-time gene therapy, Zolgensma, with an eye-popping price of $2.1 million per patient.\n\nA backlash has been growing, especially after news reports and congressional hearings exposed stories of patients rationing medicine and even dying because they couldn\u2019t afford insulin or other drugs.\n\nDrugmakers have \u201cbeen on defense more than we\u2019ve ever seen,\u201d said David Certner, legal counsel for AARP.\n\nLast year, Certner noted, Congress dealt the industry two losses: First, by increasing the discounts that drug makers must give to seniors with high drug costs who have landed in a Medicare coverage gap. Then, months later, lawmakers rejected industry efforts to reverse that change.\n\nAnd in January, the industry lost perhaps its biggest champion in Congress when Sen. Orrin Hatch, R-Utah, retired.\n\nTrump has long promised to address drug prices. On Wednesday, the administration moved ahead with a plan to allow Americans to safely and legally gain access to lower-priced medicines from abroad. So far, most of Trump\u2019s drug-price initiatives have gone nowhere. His trade team negotiated biologics protections into the USMCA.\n\nFacing public anger, Democratic resistance and the fact that Canada and Mexico had no reason to support the protections for biologics, the administration yielded. When it reached a deal with House Democrats on the USMCA last week, the biologics provision was out.\n\n\u201cClearly, getting rid of the biologic provision was a step backwards,\u201d U.S. Trade Representative Robert Lighthizer said Tuesday in an interview with the Fox Business Network. \u201cAnd that was a compromise. You know, there are consequences of the Democrats\u2019 control of the House. And that was necessary. And I\u2019m sorry about that.\u201d\n\nJeffrey Francer, general counsel for the Association for Accessible Medicines, which represents generic and biosimilar drug companies, put it another way: \u201cThe president decided not to fall on his sword for Big Pharma.\u2019\u2019\n\n___\n\nJohnson reported from Trenton, New Jersey.",
    "source_url": "www.apnews.com",
    "bias_text": "center",
    "ID": "U0lD1cr6FaCBlVyN"
}